Biodexa Pharmaceuticals (BDRX) Other Non-Current Assets (2018)
Biodexa Pharmaceuticals (BDRX) reported Other Non-Current Assets of $12.0 million for Q4 2018, down 34.75% sequentially from $18.4 million in Q2 2018.
Biodexa Pharmaceuticals (BDRX) Other Non-Current Assets (2018) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 1 years of Other Non-Current Assets data on file, last reported at $12.0 million in Q4 2018.
- For the quarter ending Q4 2018, Other Non-Current Assets changed N/A year-over-year to $12.0 million; the trailing twelve-month figure through Dec 2018 stood at $12.0 million (changed N/A YoY), and the FY2018 full-year result was $12.5 million, changed N/A from the prior year.
- Other Non-Current Assets declined to $12.0 million in Q4 2018, from $18.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $18.4 million in Q2 2018 to a low of $12.0 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 12.03 Mn |
| Jun 30, 2018 | 18.44 Mn |